This site is intended for healthcare professionals
FDA Hero  Banner - Multi-coloured pills and tablets
FDA Drug information

Ribavirin

Read time: 1 mins
Marketing start date: 03 May 2024

Summary of product characteristics


Effective Time

20230927

Version

8

Spl Product Data Elements

Ribavirin Ribavirin RIBAVIRIN RIBAVIRIN CROSPOVIDONE (15 MPA.S AT 5%) MAGNESIUM STEARATE GELATIN POVIDONE TITANIUM DIOXIDE SILICON DIOXIDE CELLULOSE, MICROCRYSTALLINE WHITE CAPSULE ZA;12;200mg

Application Number

ANDA077224

Brand Name

Ribavirin

Generic Name

Ribavirin

Product Ndc

65841-260

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-260-12 in bottle of 84 capsules Ribavirin Capsules USP, 200 mg R x only 84 capsules Ribavirin Capsules, 200 mg

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.